EC Healthcare Framtida tillväxt

Future kriterier kontrolleras 4/6

EC Healthcare förväntas öka vinsten och intäkterna med 59.8% och 8.8% per år respektive medan EPS förväntas växa med 49.3% per år.

Viktig information

59.8%

Tillväxttakt i vinsten

49.3%

Tillväxttakt för EPS

Consumer Services vinsttillväxt	20.7%
Intäkternas tillväxttakt	8.8%
Framtida avkastning på eget kapital	n/a
Bevakning av analytiker	Low
Senast uppdaterad	03 Dec 2024

Senaste uppdateringarna om framtida tillväxt

Recent updates

EC Healthcare's (HKG:2138) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 20

Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding

Sep 05

EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively

Jul 26

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 13

When Should You Buy EC Healthcare (HKG:2138)?

Apr 26

Is EC Healthcare (HKG:2138) A Risky Investment?

Feb 07

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

Dec 24

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

Dec 08

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

Dec 01

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Sep 15

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Aug 24

Is EC Healthcare (HKG:2138) Using Too Much Debt?

Aug 10

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Jul 14

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Jun 26

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

Jun 15

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

May 12

Is EC Healthcare (HKG:2138) Potentially Undervalued?

Mar 08

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Feb 03

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Dec 20

Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?

Oct 25

EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return

Sep 20

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

Sep 01

EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 28

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

Jul 14

EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042

Jun 26

When Should You Buy EC Healthcare (HKG:2138)?

May 26

EC Healthcare (HKG:2138) Will Be Hoping To Turn Its Returns On Capital Around

Apr 18

Prognoser för vinst- och omsättningstillväxt

SEHK:2138 - Analytikernas framtida uppskattningar och tidigare finansiella data (HKD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
3/31/2026	4,749	17	N/A	N/A	1
3/31/2025	4,623	67	N/A	897	2
9/30/2024	4,153	-12	632	793	N/A
6/30/2024	4,182	-15	580	741	N/A
3/31/2024	4,211	-19	528	689	N/A
12/31/2023	4,157	-11	422	709	N/A
9/30/2023	4,104	-4	317	729	N/A
6/30/2023	3,989	33	255	667	N/A
3/31/2023	3,875	70	193	605	N/A
12/31/2022	3,622	93	162	499	N/A
9/30/2022	3,369	117	132	392	N/A
6/30/2022	3,144	157	240	500	N/A
3/31/2022	2,920	198	348	608	N/A
12/31/2021	2,823	253	479	684	N/A
9/30/2021	2,727	309	610	760	N/A
6/30/2021	2,404	251	541	690	N/A
3/31/2021	2,080	193	472	621	N/A
12/31/2020	1,854	163	487	597	N/A
9/30/2020	1,627	133	503	573	N/A
6/30/2020	1,788	210	505	574	N/A
3/31/2020	1,949	287	507	576	N/A
12/31/2019	2,023	325	273	452	N/A
9/30/2019	2,098	364	40	327	N/A
6/30/2019	1,975	363	-5	283	N/A
3/31/2019	1,852	361	-49	238	N/A
12/31/2018	1,715	355	108	278	N/A
9/30/2018	1,578	348	265	317	N/A
6/30/2018	1,450	314	N/A	320	N/A
3/31/2018	1,322	279	N/A	324	N/A
12/31/2017	1,253	266	N/A	302	N/A
9/30/2017	1,183	253	N/A	280	N/A
6/30/2017	1,079	227	N/A	230	N/A
3/31/2017	975	201	N/A	180	N/A
12/31/2016	878	170	N/A	123	N/A
9/30/2016	780	139	N/A	66	N/A
6/30/2016	744	144	N/A	71	N/A
3/31/2016	708	149	N/A	76	N/A
12/31/2015	688	166	N/A	105	N/A
9/30/2015	668	183	N/A	134	N/A
6/30/2015	645	179	N/A	146	N/A
3/31/2015	621	174	N/A	159	N/A
3/31/2014	490	81	N/A	145	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: 2138 förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 2.4% ).

Resultat vs marknad: 2138 förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: 2138 förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: 2138 s intäkter ( 8.8% per år) förväntas växa snabbare än Hong Kong marknaden ( 7.8% per år).

Hög tillväxtintäkter: 2138 s intäkter ( 8.8% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om 2138 s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/09 04:53
Aktiekurs vid dagens slut	2025/03/07 00:00
Intäkter	2024/09/30
Årlig intjäning	2024/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

EC Healthcare bevakas av 9 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Tingting Li	BOCI Research Ltd.
Zhuonan Xu	China International Capital Corporation Limited
null null	China International Capital Corporation Limited

EC Healthcare Framtida tillväxt

Future kriterier kontrolleras 4/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Price target decreased by 15% to HK$5.22

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

Consensus EPS estimates fall by 31%

Recent updates

EC Healthcare's (HKG:2138) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Does EC Healthcare (HKG:2138) Have A Healthy Balance Sheet?

New major risk - Share price stability

New minor risk - Market cap size

Upcoming dividend of HK$0.01 per share

EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth

Dividend of HK$0.01 announced

First half 2025 earnings released: EPS: HK$0.012 (vs HK$0.006 in 1H 2024)

EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025

New minor risk - Market cap size

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

Less than half of directors are independent

Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024

An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

When Should You Buy EC Healthcare (HKG:2138)?

Is EC Healthcare (HKG:2138) A Risky Investment?

New minor risk - Share price stability

EC Healthcare (SEHK:2138) entered into sale and purchase agreement to acquire 6.49% stake in Pangenia Inc from Sharp Point Consultant Limited for HKD 17.4 million.

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

Price target decreased by 15% to HK$5.22

First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023

EC Healthcare Announces Executive Changes

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023

Upcoming dividend of HK$0.042 per share at 2.6% yield

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023

Is EC Healthcare (HKG:2138) Using Too Much Debt?

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Consensus EPS estimates fall by 31%

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Price target decreased by 11% to HK$8.03

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare, Annual General Meeting, Aug 23, 2023

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

Is EC Healthcare (HKG:2138) Potentially Undervalued?

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Price target increased to HK$9.33

Price target increased to HK$8.04

Upcoming dividend of HK$0.058 per share

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Investor sentiment improved over the past week

Consensus forecasts updated

First half 2023 earnings released

EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 20 January 2023

Price target decreased to HK$8.89

Less than half of directors are independent

EC Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2022